Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
112 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2015', provides an overview of the B-Cell Chronic Lymphocytic Leukemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for B-Cell Chronic Lymphocytic Leukemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the B-Cell Chronic Lymphocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the B-Cell Chronic Lymphocytic Leukemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 B-Cell Chronic Lymphocytic Leukemia Overview 9 Therapeutics Development 10 Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Overview 10 Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis 11 B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Development by Companies 12 B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Investigation by Universities/Institutes 14 B-Cell Chronic Lymphocytic Leukemia - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 B-Cell Chronic Lymphocytic Leukemia - Products under Development by Companies 18 B-Cell Chronic Lymphocytic Leukemia - Products under Investigation by Universities/Institutes 20 B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development 21 AbbVie Inc. 21 Amgen Inc. 22 BioNovion B.V. 23 Celgene Corporation 24 Dynavax Technologies Corporation 25 Eisai Co., Ltd. 26 F. Hoffmann-La Roche Ltd. 27 iDD biotech SAS 28 Immunomedics, Inc. 29 Juno Therapeutics Inc. 30 MABLife S.A.S 31 Nippon Shinyaku Co., Ltd. 32 Noxxon Pharma AG 33 Ono Pharmaceutical Co., Ltd. 34 Regeneron Pharmaceuticals, Inc. 35 SBI Biotech Co., Ltd. 36 TheraMAB LLC. 37 Vivia Biotech, S.L. 38 B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment 39 Assessment by Monotherapy Products 39 Assessment by Target 40 Assessment by Mechanism of Action 42 Assessment by Route of Administration 44 Assessment by Molecule Type 46 Drug Profiles 48 202-b - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 alemtuzumab biosimilar - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 AMG-319 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 bafetinib - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 BION-1301 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Cell Therapy for B-Cell Chronic Lymphocytic Leukemia - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Cell Therapy for Hematological Malignancies - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Cell Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Cell Therapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Cell Therapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Cell Therapy to Target CD16 for CLL and NHL - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Cell Therapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Cell Therapy to Target CD19 for Cancer - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Cell Therapy to Target CD19 for Oncology - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 E-7449 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 GNKS-356 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 IDD-001 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 IDD-002 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 ilorasertib - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 lenalidomide - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 MAT-304 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 olaptesed pegol - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 ONO-4059 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 REGN-1979 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 SD-101 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Small Molecules for Oncology - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 TAB-08 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 tocilizumab - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 Vivia-009 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 B-Cell Chronic Lymphocytic Leukemia - Recent Pipeline Updates 92 B-Cell Chronic Lymphocytic Leukemia - Dormant Projects 107 B-Cell Chronic Lymphocytic Leukemia - Discontinued Products 108 B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones 109 Featured News & Press Releases 109 Dec 12, 2011: CytRx Announces Presentation Of Favorable Phase II Results With Bafetinib In Relapsed B-Cell Chronic Lymphocytic Leukemia At ASH Conference 109 Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia 110 Appendix 111 Methodology 111 Coverage 111 Secondary Research 111 Primary Research 111 Expert Panel Validation 111 Contact Us 111 Disclaimer 112
List of Tables Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2015 10 Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H1 2015 11 Number of Products under Development by Companies, H1 2015 13 Number of Products under Investigation by Universities/Institutes, H1 2015 14 Comparative Analysis by Late Stage Development, H1 2015 15 Comparative Analysis by Clinical Stage Development, H1 2015 16 Comparative Analysis by Early Stage Development, H1 2015 17 Products under Development by Companies, H1 2015 18 Products under Development by Companies, H1 2015 (Contd..1) 19 Products under Investigation by Universities/Institutes, H1 2015 20 B-Cell Chronic Lymphocytic Leukemia - Pipeline by AbbVie Inc., H1 2015 21 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Amgen Inc., H1 2015 22 B-Cell Chronic Lymphocytic Leukemia - Pipeline by BioNovion B.V., H1 2015 23 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Celgene Corporation, H1 2015 24 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Dynavax Technologies Corporation, H1 2015 25 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Eisai Co., Ltd., H1 2015 26 B-Cell Chronic Lymphocytic Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 27 B-Cell Chronic Lymphocytic Leukemia - Pipeline by iDD biotech SAS, H1 2015 28 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Immunomedics, Inc., H1 2015 29 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Juno Therapeutics Inc., H1 2015 30 B-Cell Chronic Lymphocytic Leukemia - Pipeline by MABLife S.A.S, H1 2015 31 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 32 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Noxxon Pharma AG, H1 2015 33 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 34 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 35 B-Cell Chronic Lymphocytic Leukemia - Pipeline by SBI Biotech Co., Ltd., H1 2015 36 B-Cell Chronic Lymphocytic Leukemia - Pipeline by TheraMAB LLC., H1 2015 37 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Vivia Biotech, S.L., H1 2015 38 Assessment by Monotherapy Products, H1 2015 39 Number of Products by Stage and Target, H1 2015 41 Number of Products by Stage and Mechanism of Action, H1 2015 43 Number of Products by Stage and Route of Administration, H1 2015 45 Number of Products by Stage and Molecule Type, H1 2015 47 B-Cell Chronic Lymphocytic Leukemia Therapeutics - Recent Pipeline Updates, H1 2015 92 B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H1 2015 107 B-Cell Chronic Lymphocytic Leukemia - Discontinued Products, H1 2015 108
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.